Ixazomib is a novel induction-agnostic maintenance option for transplantation-ineligible patients with newly diagnosed multiple myeloma, a study suggests. The drug is a second generation proteasome inhibitor (PI) and the only one that can be taken orally. And according to results from the phase III TOURMALINE-MM4 trial, it significantly lowered the risk of disease progression compared ...
Ixazomib a valuable maintenance option in newly-diagnosed MM
By Sunalie Silva
9 Oct 2020